The FLICE-inhibitory protein (FLIP) plays a key role in the regulation of apoptosis triggered by death ligands. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce apoptosis in some types of tumor but not in others. To assess the possible role of FLIP in apoptosis resistance in endometrial carcinoma, we performed an immunohistochemical study on a tissue microarray composed of 95 endometrial carcinomas. We found positive signals in 43% of the cases, as well as a significant difference in FLIP expression between stage I and II tumors. Moreover, we observed that endometrial carcinoma cell lines Ishikawa and KLE did not undergo apoptosis after TRAIL treatment. 
Apoptosis is an important process that regulates homeostasis in multicellular tissues. Alterations in proteins that regulate apoptosis may result in impaired cell death and the development and progression of cancer. 1 The tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) belongs to the proapoptotic cytokines of the tumor necrosis factor (TNF) superfamily. Several lines of evidence have shown that TRAIL induces apoptosis in many types of cancer with limited cytotoxicity on normal cells 2, 3 indicating that it may become a promising anticancer agent. 4 TRAIL can bind four different receptors DR4/TRAIL-R1, 5, 6 DR5/TRAIL-R2, 7, 8 DcR1/TRAIL-R3, 9 and DcR2/TRAIL-R4. 10 DR4 and DR5 are functional receptors that transduce apoptosis after ligation with TRAIL. DcR1 and DcR2, known as decoy receptors, lack the intracellular domains required to induce apoptosis. Recently, it has been shown that osteoprotegerin (OPG) can also bind TRAIL with less affinity. 11 Engagement of receptors DR4 or Dr5 results in the formation of a death-inducing signalling complex (DISC). The intracellular death domain (DD) of these receptors recruits Fas associated DD-containing protein (FADD), which in turn binds procaspase-8. After recruitment to the DISC, procaspase-8 is activated by autoproteolytic cleavage resulting in the initiation of apoptotic signalling. [12] [13] [14] Active caspase-8 activates the executioner caspase-3, which in turn cleaves the cellular substrates.
The FLICE-inhibitory protein (FLIP) was initially described as a homologue of viral v-FLIP, which is a key regulator of death-receptor signalling. 15, 16 Two isoforms of FLIP are generated by alternative splicing: the long form, FLIP-L; and the short form, FLIP-S. 16 Both proteins share a high degree of homology with caspase-8, and contain two Death Effector Domains (DED). FLIP-L also contains a caspase-like domain but lacks proteolytic activity. Therefore, high levels of expression of FLIP result in inhibition of caspase-8 activation and apoptosis triggered by death receptors. Recent evidence indicates that FLIP is constitutively or highly expressed in some tumors such as prostate cancer, 17 Hodgkin's lymphoma, 18 gastric cancer, 19 bladder carcinoma, 20 and malignant mesothelial cell lines. 21 Although TRAIL induces apoptosis in a wide variety of neoplastic cells, certain tumors are resistant to TRAIL killing. The potential use of TRAIL in cancer therapy increases interest in the understanding of the molecular mechanisms by which tumor cells are resistant to TRAIL.
In this article, we provide evidence for the first time that suggests that FLIP may be important in apoptosis resistance in endometrial carcinoma. First, we show that FLIP is frequently expressed in endometrial carcinoma and correlates with stage. Moreover, we show that Ishikawa and KLE cell lines are resistant to TRAIL-induced apoptosis. Inhibition of transcription by actinomycin D results in cell viability decrease and induction of apoptosis. The sensitization to TRAIL by actinomycin D correlated with a significant reduction on FLIP expression and forced expression of FLIP overcame TRAIL plus actinomycin D-induced apoptosis. Moreover, downregulation of endogenous FLIP by siRNA was sufficient to sensitize endometrial carcinoma cells to TRAIL-induced apoptosis.
Materials and methods

Tissue Microarray Construction and Immunohistochemistry
A tissue microarray (TMA) was constructed from paraffin-embedded blocks of 95 endometrial carcinomas (EC), obtained from A tissue array device (Beecher Instruments, MD, USA) was used. All ECs were histologically reviewed and representative tumor areas were marked in the corresponding paraffin blocks. Two selected cylinders (0.6 mm in largest diameter) from two different tumor areas were included for each case.
Normal control tissues from the same specimens were also included. Thus, two different TMAs blocks were constructed; each of them contained 186 cylinders.
TMA blocks were sectioned at a thickness of 3 mm, dried for 16 h at 561C. They were dewaxed in xylene, rehydrated through a graded ethanol series, and washed with phosphate-buffered saline. Antigen retrieval was achieved by heat treatment in a pressure-cooker for 3 min in 10 mM citrate buffer (pH 6.5). Endogenous peroxidase was blocked. A rabbit polyclonal antibody, against aminoacids 1-202 at the amino terminus of FLIP was used (H-202, Santa Cruz, Santa Cruz, CA, USA; dilution 1:10). After incubation, the reaction was visualized with the EnVision Detection Kit (DAKO, Glostrup, Denmark) using diaminobenzidine chromogen as substrate. Sections were counterstained with hematoxylin. Appropriate external and internal positive and negative controls were used. Antigen preservation was verified with vimentin and Ki-67 immunostaining.
Immunohistochemistry was evaluated by two pathologists who followed uniform pre-established criteria. Immunoreactivity was graded semiquantitatively by considering the percentage and intensity of the staining.
A histological score was obtained from each sample, which ranged from 0 (no immunoreaction) to 300 (maximum immunoreactivity). The score was obtained by applying the following formula Hscore ¼ 1X (% light staining) þ 2X (% moderate staining) þ 3X (% strong staining). Since each TMA included two different tumor cylinders from each case, immunohistochemical evaluation was performed after examining both samples. The apoptotic index was calculated by the percentage of apoptotic bodies in H&E-stained sections, after evaluating a minimal number of 1000 cells.
The reproducibility of TMA immunostaining was confirmed by comparison of TMA results with those obtained in sections from the corresponding paraffin blocks of 37 randomly selected cases. The overall concordance was 89.2%. The Kappa index of agreement between the two methods ranged from 0.68 to 0.83.
FLIP immunostaining was correlated with histological type and grade, stage, and the apoptotic index. The Fisher's exact test was used to assess association between categorical variables. The Wilcoxon rank sum and the Kruskal-Wallis tests were used to assess association between continuous and categorical variables. The Spearman rank correlation test was used to assess association between continuous and/or ordinal variables. 
Western Blot Analysis
Endometrial carcinoma cell lines were washed with cold PBS and lysed with lysis buffer (2% SDS, 125 mM Tris-Hcl pH 6.8). Protein concentrations were determined with the Protein assay Kit (BioRad, Richmon, CA, USA). Equal amounts of proteins were subjected to SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA). 
Caspase-8 Activity
Cells were treated with the indicated conditions for 12 h and harvested with lysis buffer containing 50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% 3-[(3 cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS), 10% saccharose, 5 mM dithiothreitol. Cell lysates were centrifuged at 10 000 g, and protein extracts were quantified with the Protein assay Kit (Bio-Rad, Richmon, CA, USA). Equal amounts of protein were loaded on M96 multiwell plates and the colorimetric substrate Nacetyl-Ile-Glu-Thr-Aspp-nitroanilide (Ac-IETDpNA) (Biomol, Plymouth, PA, USA) was added. Samples were incubated at 371C, and the absorbance at 405 nm was read in a microplate reader. Results were expressed as a fold induction over basal.
Cell Viability Assays and Assessment of Apoptosis
Cell viability was determined by MTT assay. Endometrial carcinoma cells were plated on M96 well plates at 15 Â 10 3 cells per well. After the indicated treatments, cells were incubated for 2-3 h with 0.5 mg/ml of MTT reagent, lysed with DMSO. Absorbance was measured at 595 nm in a microplate reader (Bio-Rad, Richmon, CA, USA).
Hoechst staining was performed by adding Hoechst dye to a final concentration of 0.5 mg/ml to each M96 well. Cells were counted under epifluorescence microscope (Leica Microsystems).
RNA Extraction and RT-PCR
Total RNA was extracted using the TRIZOL reagent (Invitrogen Inc., Carlsbad, CA, USA) as indicated by the manufacturer. Of total RNA, 1 mg was subjected to reverse transcription for 1 h at 421C with the Multiscrive reverse transcription kit (Applied biosystems Inc., Foster City, CA, USA). cDNA was amplified by PCR using FLIP-specific set of primers (forward: 5 0 -GGACCTTGTGGTTGAGTTGG-3 0 , reverse: 5 0 -TCTTCACTGGTTCTTGTTGAGC-3 0 ) for each gene plus the actin primers. Cycling conditions were as follows: 45 s at 941C, 45 s at 551C and 45 s at 721C for 31 cycles. PCR products were resolved in an 8% acrylamide-bisacrylamide gel.
Results
FLIP is Frequently Expressed in Endometrial Carcinoma, and Shows a Correlation with Stage
In all, 10 cylinders were missed in either the construction of the tissue microarray, section or staining procedures. Six cases were excluded because of unreliable staining of vimentin and Ki-67. Thus, FLIP immunostaining was evaluated, in at least one cylinder, in 88 cases. Cytoplasmic staining was observed in 34 cases (43%), and the Hscore varied from 0 to 170 (mean ¼ 33.98) (Figure 1 ). There was a statistically significant difference in FLIP expression between Stage I and II tumors (P ¼ 0.016). The mean Hscore was 25.74 for stage I tumors, and 62.7 for stage II tumors. However, FLIP staining did not show statistically significant correlation with histological type (P ¼ 0.723), grade (P ¼ 0.914) or apoptotic index (P ¼ 0.177) ( Table 1) .
Actinomycin D Downregulates FLIP and Sensitizes Endometrial Carcinoma Cells to TRAIL-Induced Apoptosis
TRAIL is able to induce apoptosis in a wide variety of tumor cells. However, several types of tumors FLIP in endometrial carcinoma X Dolcet et al display TRAIL resistance. First, we explored the ability of endometrial carcinoma cell lines to undergo apoptosis after TRAIL treatment. IK and KLE cells were treated for several days with 50 ng/ml of TRAIL. Exposure to TRAIL even for long periods of time did not significantly reduce the viability of either cell line. Only a 5-10% reduction in cell viability was observed during the first 24-72 h in culture (Figure 2a) .
A classical approach to sensitize resistant cells to TRAIL-triggered apoptosis is the inhibition of transcription or translation. FLIP in endometrial carcinoma X Dolcet et al be involved in TRAIL resistance to apoptosis in endometrial carcinoma.
Overexpression of FLIP-L Overcomes TRAIL-Induced Apoptosis
To ascertain whether high levels of FLIP rescue endometrial carcinoma cell lines from TRAIL plus actinomycin D-induced apoptosis, we transiently transfected IK cells with a plasmid coding for FLIP-L. After 24 h of transfection to allow FLIP-L expression, cells were treated with TRAIL or TRAIL plus actinomycin D and apoptotic nuclei were visualized by Hoechst staining. As shown in Figure 4, 
Discussion
Apoptosis is a key process in the regulation of cellular homeostasis. Alterations of apoptosis plays an important role in development and progression of cancer. Deregulation of proteins involved in apoptosis control may result in cell populations that escape of apoptotic cell death. 1 The lack of response to such stimuli can produce a survival advantage, and the expansion of a population of neoplastic cells. Moreover, defects in the apoptotic pathway can make cancer cells resistant to therapy.
Several proapoptotic members of the TNF superfamily trigger the 'extrinsic' apoptotic pathway. 23 Among these members, TRAIL has raised interest as a potential anti-cancer agent, because of its ability to trigger apoptosis in cancer cells without affecting normal cells. 2, 3 However, an increasing number of tumor types show mechanisms of TRAIL resistance. In these tumors, cell death is blocked as a result of molecular alterations of proteins regulating extrinsic apoptotic pathway. In the present study, we demonstrated that FLIP is frequently expressed in endometrial carcinoma cells and suggested, for the first time, that FLIP may play a significant role in resistance of endometrial cancer cells to TRAIL-induced apoptosis.
The results of the present study showed that FLIP expression is frequent in endometrial carcinomas. Interestingly, FLIP expression did not correlate with histological type or grade, suggesting that it may be involved in the process of apoptosisresistance of both type I (endometrioid) and type II (nonendometrioid) endometrial carcinomas. These two types of endometrial carcinomas do not show only different morphological features, but exhibit significant clinical and molecular differences. 24 The possible effects of FLIP and TRAIL in the development of apoptotic cell death in endometrial carcinoma cells have not been addressed so far. We first assessed the viability of two endometrial carcinoma cell lines after exposition to TRAIL. Treatment of both IK and KLE with TRAIL failed to cause a significant reduction on viability. Only a marginal reduction of 5-10% was observed on the first 24-72 h in culture. However, incubation of these cell lines with actinomycin D (an inhibitor of transcription) plus TRAIL resulted in a marked decrease of cell viability caused by apoptotic death. Treatment with inhibitors of transcription or translation, such as actinomycin D or cycloheximide, has been shown to be effective in sensitization of different tumor cells to members of the TNF superfamily. These inhibitors may cause the reduction of the expression of some intracellular proteins that inhibit different steps of the apoptotic cascade. The results obtained with actinomycin D treatment indicate that these endometrial carcinoma cell lines may express molecules that are able to block TRAIL-induced apoptosis. Consistently, the cell death caused by actinomycin treatment is accompanied by an increase of caspase-8. These results enabled us to study intracellular proteins involved in the regulation of apoptotic signalling by TRAIL. One of such regulators is FLIP, which competes with caspase-8 for the binding to FADD. Therefore, the expression of FLIP could be important as a mechanism to suppress apoptosis.
An RT-PCR and Western blot analysis on a time course exposition to actinomycin D showed a marked decrease in the levels of both FLIP mRNA and protein suggesting that FLIP could be one of the mechanisms of this resistance. These results are concordant with previous studies that found decreased levels of FLIP after treatment with inhibitors of transcription. 25, 26 To investigate whether the decreased FLIP expression was responsible for TRAIL resistance, we transfected endometrial carcinoma cells with a plasmid coding for FLIP. The transfection assays resulted in a prevention of TRAIL-induced apoptosis, which indicated that actinomycin D regulates the activation of the extrinsic apoptotic pathway. Furthermore, the incubation of the endometrial carcinoma cells with an inhibitor of caspase-8 (z-IETD-fmk) resulted in a complete inhibition of apoptosis. Altogether, these data provide evidence that FLIP is, at least, one of the proteins that are involved in apoptosis resistance to TRAIL.
Direct evidence of the role of endogenous FLIP in TRAIL apoptosis resistance on endometrial carcinoma cells is provided by treatment with specific This was accompanied by processing of both caspase-8 and caspase-3 suggesting activation of the extrinsic pathway. The fact that endogenous FLIP inhibition induced apoptosis indicates that FLIP is necessary and sufficient to cause resistance to TRAIL-induced apoptosis. KLE cells showed an increase of apoptotic nuclei as well as caspase-3 and caspase-8 processing after 24 h of transfection with FLIP siRNA, but without exogenous supplied TRAIL to the medium. This result suggests that KLE cells may produce an endogenous factor that may promote self-induced cell death in an autocrine manner.
Although several studies have demonstrated an anti-apoptotic role for FLIP by interfering caspase-8 recruitment to the DISC, some recent evidences suggest that the amount of FLIP that is present in the DISC may be responsible for either suppressing or inducing apoptosis. 27 Thus, FLIP may cause activation of both caspase-8 and caspase-10. 28, 29 Our findings demonstrated that in endometrial carcinoma cell lines, the endogenous levels of expression of FLIP may inhibit caspase activation. The results also showed that downregulation of FLIP enables caspase cleavage and apoptosis.
There is evidence suggesting a possible role of FLIP in the resistance to apoptosis in cancer. FLIP is a human cellular homologue of viral FLICE-inhibitory proteins, which are expressed by g-herpes viruses, and were shown to be capable of blocking CD95-mediated apoptosis through association with the receptor in the DISC. 16 In cells that are latently infected with human herpes virus 8, v-FLIP is expressed at low levels but its expression is increased in Kaposi sarcomas. Human melanomas and a murine B-cell lymphoma cell line have been shown to express high levels of FLIP, which interferes with apoptosis induction by death receptors. On the other hand, there is high constitutive expression of FLIP in Reed-Sternberg cells of Hodgkin's lymphomas; and some evidences suggest that it prevents FAS-induced apoptosis in these cells. 30, 18 There are also evidences that FLIP may inhibit the extrinsic apoptotic pathway in carcinomas of the prostate, 17 the stomach, 19 and the urinary bladder, 20 and melanoma. 31 On the other hand, FLIP has also been shown to be expressed in ovarian cancer, 32 a gynecologic type of tumor very similar to endometrial carcinoma. Interestingly, in some types of tumor, such as in carcinomas of the urinary bladder, FLIP expression was shown to correlate with advanced stage. 20 Similarly, in the present series, FLIP expression also showed a statistically significant difference between stage I and II endometrial carcinomas, which may suggest that resistance to TRAIL-mediated apoptosis could be related to tumor progression.
Finally, it is worth mentioning that FLIP is an important target of the nuclear factor-Kappa B (NFkB) signalling pathway. 33 NF-kB encompasses different members of a family of transcription factors, involved in the regulation of genes encoding cytokines, cytokine receptors, and cell adhesion molecules, that drive immune and inflammatory responses. However, NF-kB has been recently found related to carcinogenesis, by regulating genes involved in apoptosis, the cell cycle, differentiation, and cell migration. In a previous study, we demonstrated that NF-kB family members are frequently expressed in endometrial carcinomas. 34 Although assessment of FLIP expression was not the main goal of that study, we tried to correlate FLIP and NF-kB expression, but we did not find any statistical association between them. However, it is important to emphasize that increased expression of FLIP may result from activation of some signalling pathways, other than NF-kB.
In summary, we provide evidence that FLIP is expressed in endometrial carcinoma, and that it may 
FLIP in endometrial carcinoma
X Dolcet et al be responsible for resistance to TRAIL-induced apoptosis in this type of tumor.
